Eagle Pharmaceuticals, inc. (EGRX)

[Bickema]

In regards to milestone, the answer is yes

With the J-Code decision, the company's royalty rate has increased from 20% to 25% on Teva's US sales of Bendeka, effective November 1. In addition, we will receive a milestone payment of $40 million. Finally, we believe we will reach the accumulative sales milestone in January of next year, entitling us to another $25 million milestone payment. Altogether, we expect to receive approximately $100 million one more from Teva over the next few months.